Interchangeable Biosimilars Market - Top Companies and Manufacturers

Companies Dominating the Interchangeable Biosimilars Landscape

Biocon Limited
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Mylan N.V.
Amgen Inc.
Coherus BioSciences, Inc.
Pfizer Inc.
Sandoz International GmbH
Merck & Co.
Boehringer Ingelheim group
Samsung Bioepis Co., Ltd.
Teva Pharmaceutical Industries Ltd.

Browse Key Market Insights with Data Illustration:

Interchangeable Biosimilars Market Size & Share, Growth Analysis 2035

In the News

Samsung Bioepis Co., Ltd. and Biogen Canada Inc. announced the approval of BYOOVIZ by Health Canada. BYOOVIZ is a biosimilar referencing LUCENTIS (ranibizumab).
Sandoz International GmbH, a global leader in generic and biosimilar medicines, announced the submission of a Biologics License Application for biosimilar trastuzumab to the US Food and Drug Administration (FDA).

Frequently Asked Questions (FAQ)

Increasing incidences of chronic diseases and the growing availability of over-the-counter drugs along with the rising focus on health and fitness are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 20% over the forecast period, i.e., 2023-2035.

Stringent regulations regarding the approval of biosimilars coupled with high-cost associated with interchangeable biosimilars are estimated to be the growth hindering factors for the market expansion.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Biocon Limited, Mylan N.V., Amgen Inc., Coherus BioSciences, Inc., Pfizer Inc., Sandoz International GmbH, Merck & Co., Boehringer Ingelheim group, Samsung Bioepis Co., Ltd., Teva Pharmaceutical Industries Ltd., and other key players.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by disease type, application, end-users, and by region.

The cancer segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities

Interchangeable Biosimilars Market - Top Companies and Manufacturers

Companies Dominating the Interchangeable Biosimilars Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the interchangeable biosimilars market?

What would be the CAGR of interchangeable biosimilars market over the forecast period?

What are the challenges affecting the interchangeable biosimilars market growth?

Which region will provide more business opportunities for growth of interchangeable biosimilars market in future?

Who are the major players dominating the interchangeable biosimilars market?

How are the company profiles selected?

What are the segments in the interchangeable biosimilars market?

Which segment captures the largest market size in disease type segment in the interchangeable biosimilars market?